Outlook Therapeutics OTLK 深 沪
等待开盘 08-02 09:30:00 美东时间
1.93
-0.030
-1.53%
华盛通- 最 高1.96
- 今 开1.95
- 成交量 66.94万股
- 最 低 1.86
- 昨 收 1.96
- 总市值 8270.76万
- 52周最高 8.32
- 市盈率 静 --
- 换手率 1.56%
- 52周最低 0.87
- 委 比 68.15%
- 总股本 4285.37万
- 历史最高 219.20
- 量 比 0.90
- 振 幅 5.10%
- 历史最低 1.06
- 每 手 1
- 风险率 2.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Outlook Therapeutics, Inc. will present at the 8th Annual OIS Retina Innovation Summit on July 29, 2025 in Long Beach, CA. CEO Bob Jahr will discuss the company's ophthalmic bevacizumab product, LYTENAVA™, which is the first approved formulation for treating wet AMD in Europe and the UK. The company has resubmitted a BLA for FDA approval in the U.S., aiming to become the first approved ophthalmic bevacizumab for retinal indications.
07-24 13:00
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Outlook Therapeutics, Inc.的首席执行官Bob Jahr参加了投资者在线会议，分享了他加入公司的背景及对未来的展望。该会议的视频回放可在virtualinvestorco.com和公司网站上观看。该公司专注于开发眼科药物LYTENAVA™，已在欧洲和英国上市，目前在美国处于审批阶段。
07-22 12:45
Outlook Therapeutics announces CEO appointment
Outlook Therapeutics (NASDAQ:OTLK) has named Bob Jahr as chief executive officer and a member of its board. Jahr succeeds interim CEO Lawrence A. Kenyon, who will continue as chief financial officer a...
07-01 20:22
Outlook Therapeutics Appoints Bob Jahr As CEO
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographiesCareer focused on driving business growth and developing an integrated
07-01 20:12
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
Outlook Therapeutics, Inc. appoints Bob Jahr as CEO, bringing over 20 years of biopharmaceutical experience. Jahr joins as the company launches its ophthalmic formulation of bevacizumab in Europe and seeks FDA approval in the U.S. His leadership aims to enhance the company’s commercial strategy and stakeholder value. Additionally, an option for 800,000 shares was granted to Jahr, vesting over four years, reflecting the company’s confidence in his...
07-01 12:05
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
Outlook Therapeutics, Inc. will participate in a Virtual Investor Lunch Break Event on June 25, 2025, at 12:00 PM ET. Lawrence Kenyon, Jeff Evanson, and Jedd Comiskey will discuss the company's commercial strategy, upcoming milestones, and current activities. Investors can submit live questions during the event. A live video webcast will be available on the company's website, with a replay accessible for 90 days. Outlook Therapeutics focuses on d...
06-18 13:05
Outlook Therapeutics Secures SMC Approval For LYTENAVA As First And Only Licensed Ophthalmic Bevacizumab For Wet AMD Treatment In UK, Has An Initial 10 Years Of Market Exclusivity From The Date Of Initial Marketing Authorization From The Medicines And Healthcare Products Regulatory Agency
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium
06-10 20:10
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
Outlook Therapeutics Launches First-Ever Eye Drug Bevacizumab for Wet AMD in Germany and UK
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab
06-02 19:09
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
<p>LYTENAVA™, an approved ophthalmic formulation of bevacizumab, is now commercially available in Germany and the UK for treating wet age-related macular degeneration (wet AMD). It is the first and only authorized formulation for this purpose in the European Union and UK. With approximately 2.8 million injections of repackaged off-label bevacizumab used annually in Europe, LYTENAVA™ aims to mitigate risks associated with current off-label use. Ou...
06-02 11:00
